Compugen Ltd.
Triple combination antibody therapies
Last updated:
Abstract:
The present invention is directed to triple combination therapies with anti-TIGIT antibodies, anti-PVRIG antibodies, and checkpoint inhibitors, including anti-PD-1 or anti-PD-L1 antibodies.
Status:
Grant
Type:
Utility
Filling date:
1 Jun 2018
Issue date:
18 Jan 2022